Evidence
J Med Chem. 2024 Jan 2. doi: 10.1021/acs.jmedchem.3c01868. Online ahead of print.
ABSTRACT
The V1a receptor is a major contributor in mediating the social and emotional effects of arginine-vasopressin (AVP); therefore it represents a promising target in the treatment of several neuropsychiatric conditions. The aim of this research was to design and synthesize novel and selective V1a antagonists with improved in vitro and in vivo profiles. Through optimization and detailed SAR studies, we developed low nanomolar antagonists, and further characterizations led to the discovery of the clinical candidate compound 43 (RGH-122). The CNS activity of the compound was determined in a 3-chamber social preference test of autism in which RGH-122 successfully enhanced social preference with the lowest effective dose of 1.5 mg/kg.
PMID:38165765 | DOI:10.1021/acs.jmedchem.3c01868
Add to Google Keep
Post to X
Share on Linkedin
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Discovery and Characterization of RGH-122, a Potent, Selective, and Orally Bioavailable V1a Receptor Antagonist
🌐 90 Days
VR Related Evidence Matrix
Evidence Blueprint
Discovery and Characterization of RGH-122, a Potent, Selective, and Orally Bioavailable V1a Receptor Antagonist
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Discovery and Characterization of RGH-122, a Potent, Selective, and Orally Bioavailable V1a Receptor Antagonist
🌐 365 Days
VR Related Evidence Matrix
